Rifamycin PR-14
Product Code: AG-CN2-0334
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CN2-0334-M010 | 10 mg | £120.00 |
Quantity:
| AG-CN2-0334-M050 | 50 mg | £450.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
NCI 143-462; NSC 143462; BRN 5402462; Rifamycin PR 14; 3'-Acetyl-1',2'-dimethyl-rifamycin II
Appearance:
Yellow to orange powder.
CAS:
21240-38-0
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.Protect from light when in solution.
InChi:
InChI=1S/C43H54N2O12/c1-18-14-13-15-19(2)42(53)44-33-30-28(25(8)46)24(7)45(11)34(30)29-31(38(33)51)37(50)23(6)40-32(29)41(52)43(10,57-40)55-17-16-27(54-12)20(3)39(56-26(9)47)22(5)36(49)21(4)35(18)48/h13-18,20-22,27,35-36,39,48-51H,1-12H3,(H,44,53)/b14-13+,17-16+,19-15-/t18-,20+,21+,22+,27?,35-,36+,39+,43-/m0/s1
InChiKey:
MVODEXRQKZLCBL-UWZZLQTBSA-N
Long Description:
Chemical. CAS: 21240-38-0. Formula: C43H54N2O12. MW: 790.9. Semisynthetic. Ansamycin antibiotic. Selective inhibitor of bacterial DNA-dependent RNA polymerase (RNAP). Effective against mycobacteria, and are therefore used in research of tuberculosis, leprosy and mycobacterium avium complex (MAC) infections.
Molecular Formula:
C43H54N2O12
Molecular Weight:
790.9
Package Type:
Vial
Product Description:
Ansamycin antibiotic. Selective inhibitor of bacterial DNA-dependent RNA polymerase (RNAP). Effective against mycobacteria and therefore used in research of tuberculosis, leprosy and Mycobacterium avium complex (MAC) infections.
Purity:
>98% (HPLC)
SMILES:
OC1=C(NC(/C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@H]([C@@H](C)[C@@H]([C@H](C)[C@H](/C=C/O2)OC)OC(C)=O)O)=O)C3=C(N(C)C(C)=C3C(C)=O)C4=C5C(O[C@@]2(C)C5=O)=C(C)C(O)=C41
Solubility Chemicals:
Soluble in DMSO, aqueous acetonitrile or ethanol.
Source / Host:
Semisynthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Rifamycin antibiotics: inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts: S.S. Yang, et al.; J. Natl. Cancer Inst. 49, 7 (1972) | Rifamycin Derivatives Strongly Inhibiting RNA>DNA Polymerase (Reverse Transcriptase) of Murine Sarcoma Viruses: C. Gurgo, et al.; J. Natl. Cancer Inst. 49, 61 (1972) | Isolation and characterization of human DNA-dependent RNA polymerase: M.-J. Tsai & G.F Saunders; Biochim. Biophys. Acta 366, 61 (1974) | Effect of the rifamycin dimers on the activities of nucleic acid polymerases from various sources. Relation between lipophily and toxicity: M. Talpaert-Borle, et al.; J. Antibiot. 28, 580 (1975) | Structure-Activity Relationships and DNA Polymerases From Normal and Specificity of Inhibition of Leukemia Cells of Man and From Simian Sarcoma Virus by Rifamycin Derivatives: R.A. CiCioccio & B.I.S. Srivastava; J. Natl. Cancer Inst. 61, 1187 (1978)
Related Products
| Product Name | Product Code | Supplier | Rifamycin AF | AG-CN2-0321 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifamycin AF-API | AG-CN2-0325 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AF-EPTAPI | AG-CN2-0326 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AF-DA | AG-CN2-0328 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AG | AG-CN2-0329 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AMI-DA | AG-CN2-0330 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AMP-DA | AG-CN2-0331 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin M14 | AG-CN2-0332 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin O | AG-CN2-0333 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin PR-3 | AG-CN2-0335 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin S, 8-Methyl- | AG-CN2-0337 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||